How to use BAQSIMI?
Show your family, friends, or coworkers where you keep BAQSIMI and explain how to use it by sharing these instructions.
They need to know how to use BAQSIMI before you need it.
IMPORTANT
- Do not remove the shrink wrap or open the tube until ready to use
- Do not test the device before use, as it contains only one dose of glucagon and can only be used once
- Only use BAQSIMI in the nose
- Read the BAQSIMI Patient Medication Information found inside the product box before using
Preparing the Dose:
Remove the shrink wrap by pulling on the red stripe
Open the lid and remove the device from the tube
Giving the Dose:
Hold the device between fingers and thumb
Do not press the plunger before insertion into the nose. Otherwise, the single dose in the device will be lost
Insert the tip gently in a nostril until the finger touches the outside of the nose.
Push the plunger firmly all the way in
The dose is complete when the green line is no longer showing
Watch the following video to learn how to administer BAQSIMI or read the steps below. Share it with your family, friends or coworkers so they can administer BAQSIMI in case of emergency.
Click Here to Watch Instructions for Use VideoAfter Giving the Dose:
Remove the tip from the nose and throw away the used device and tube.
Call for medical help right away.
If the person with low blood sugar is unconscious, turn the person on their side.
Medical help should be called immediately in the event of a serious allergic reaction to BAQSIMI, such as:
- Rash
- Difficulty breathing
- Swollen face, lip, tongue, or throat
Patients usually respond within 15 minutes. Encourage the person to eat as soon as they can safely swallow. Give the person a fast-acting source of sugar, like juice or regular soda. Then give the person a long-acting source of sugar, like crackers and cheese or a sandwich with meat.
Caution: Replace the used BAQSIMI right away so you will have a new BAQSIMI in case you need it.
See BAQSIMI Basics for information about storage and expiration of BAQSIMI.
Clinical use:
BAQSIMI has not been studied in pediatric patients less than 4 years old.
Limited clinical trial experience has not identified difference in responses between elderly (≥65 years of age) and younger patients.
Contraindications:
- Hypersensitivity to glucagon or to any ingredient in the formulation or container
- Pheochromocytoma
- Insulinoma
Most serious warnings and precautions:
Lack of response: BAQSIMI should be given only in patients where impaired consciousness precludes oral carbohydrates. After intranasal administration of BAQSIMI, the patient will normally respond within 15 minutes. If the patient does not respond within 15 minutes, intravenous glucose must be administered as soon as IV access can be established.
States of starvation, adrenal insufficiency or chronic hypoglycemia: Because glucagon is of little or no help in these cases, intravenous glucose should be used for the treatment of hypoglycemia in these conditions.
Other relevant warnings and precautions:
- Cardiovascular effects
- Driving and operating machinery
- Pheochromocytoma
- Insulinoma
- Sensitivity and resistance to glucagon
- Pregnant women
- Breast-feeding
- Pediatrics (<4 years of age)
- Geriatrics (≥65 years of age)
- Use in patients with Type 2 diabetes taking sulfonylureas
- Use with alcohol
- Monitoring and laboratory tests
For more information:
Consult the Product Monograph at
http://pi.lilly.com/ca/baqsimi-ca-pm.pdf
for additional important information relating to warnings and precautions, adverse reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-888-545-5972.